site sponsored by
-
Good Suppliers - And The Other Guys
18 March 2010
Is it just me, or is the fine chemicals supply business getting even more out of hand than usual?
Posted in: In the Pipeline Comments
-
Dietary Supplements, Charted
17 March 2010
I'm a complete sucker for dense but well-presented information, and this one isn't bad at all: here's a chart of nutritional supplements by the strength of the evidence for them in human trials. I haven't cross-checked the data, but the authors appear to have done some homework in PubMed, at least, and haven't included any non-human or in vitro data. The interactive version at the link is particularly fun to mess around with.
Posted in: In the Pipeline Comments
-
Theft at Eli Lilly
17 March 2010
$75 million dollars worth of antipsychotics - that's a lot of pills, and I'm not surprised to see that the thieves used a tractor-trailer to haul everything off.
Posted in: In the Pipeline Comments
-
How Social Media is Communications Around Public Health Crises
17 March 2010
It has been striking how many earthquakes there have been lately.
Posted in: Regulatory Comments
-
Science Buildings: Good, Bad, and Weird
17 March 2010
The entries I've done on the "open-plan" Biochemistry building at Oxford (see also Jim Hu ) generated a lot of comments from people who've worked in poorly designed science facilities.
Posted in: In the Pipeline Comments
-
More Blogroll
17 March 2010
Here's another addition: A New Merck, Reviewed , which is someone's attempt to dig through everything about the new Merck/Schering-Plough hybrid. I'm not sure that all the info is reliable, of course, and whoever writes this has a strange way with italics> /i> , but it's worth a look.
Posted in: In the Pipeline Comments
-
Novartis Proposes Use of Unique FDA-Approved Short URLs & Hashtags to Overcome Space Limitation Issues of Social Media
17 March 2010
Novartis submitted 6 pages of comments to Docket No. FDA‐2009‐N‐0441 regarding Promotion of FDA‐Regulated Medical Products Using the Internet and Social Media Tools ( find it here ). Novartis made many interesting proposals on how FDA should regulate the use of social media by drug companies, but I'd like to focus on one of particular interest to me: special FDA-sanctioned short URLs and hashtags that make it easy for consumers to find product-safety information and for the FDA to review social media communications for compliance.
Posted in: Web Marketing Comments
-
Should Sanofi-Aventis Submit an Adverse Event Report Based on "Disgruntled Patient’s" Comments to VOICES FB Page?
17 March 2010
Sanofi-Aventis (S-A) submitted 14 pages of comments to Docket No. FDA‐2009‐N‐0441 regarding Promotion of FDA‐Regulated Medical Products Using the Internet and Social Media Tools ( find it here )
Posted in: Traditional Strategies, Web Marketing Comments
-
BioTime’s Cellular Aging Results
17 March 2010
A small company called BioTime has gotten a lot of attention in the last couple of days after a press release about cellular aging. To give you an idea of the company's language, here's a quote: "Normal human cells were induced to reverse both the "clock" of differentiation (the process by which an embryonic stem cell becomes the many specialized differentiated cell types of the body), and the "clock" of cellular aging (telomere length)," BioTime reports
Posted in: In the Pipeline Comments
-
eHealth ready to move?
16 March 2010
The Wall Street Journal looks at the current state of eHealth, an online health insurance search engine. While the stock prices have stalled for this search engine, which compares prices of health plans much like the prices of airlines on Orbitz, it could be growing in the future.
Posted in: Web Marketing Comments
Ask Our Experts
Heather R. Powell
Regulatory
Dawn Obermoeller
Social Media
Jonathan Richman
Non-Personal Promotion
Optimize RX
Internet Marketing & Analytics
Share Your Knowledge
We are always seeking seasoned pharmaceutical marketing professonals as contributors. If you have a strong background in pharmacetical marketing, and are interested in sharing your skills and knowledge with our community, or syndicating your existing blog posts, please click here.
- Popular
- Latest
- Comments
- Tags
- Subscribe
- Valeant to Acquire Branded Generics/OTC Company in Brazil
- Zyrtec – For effective allergy relief
- According to Follower Wonk, I Have More Followers in Common with Pfizer Than Other "Experts"
- Judge gives Medicines Co. another chance
- OSI reports European recommendation on Tarceva
- Astellas Pharma meets antitrust condition in takeover attempt of OSI Pharmaceuticals
- A.P. Pharma nausea drug hit with FDA rejection
- Roche CEO Schwan Puts Science First in Pursuing Deals
- Concentric – Is your agency getting flabby?
- Ixprim – Sans douleur, la vie s’exprime
- Optimize RX: yep - recvd - thanks - how much daily u.v.'s r u g...
- JMB: This is another bashing article from an author who...
- Martin: It's just silly of you to obsess over the possibil...
- Gregg Feris: Jon, Thanks for the in depth reply. I like the ...
- Doc: Why should Exxon have to pay this fine for somethi...
Stay up to date
- Subscribe to the RSS Feed
